GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane
GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. The UK pharma is teaming with Suzhou-based SiranBio, the little-known ...
May 6, 2026 09:39 AM EDTUpdated 10:03 AM DealsChinaPharma GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane Kyle LaHucik Biotech Correspondent GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that